Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02658890 | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | completed | Phase 1 / Phase 2 | 627 | Bristol-Myers SquibbINDUSTRY | 11 | Aug 28, 2023 | clinicaltrials |
| NCT02515227 | Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab(Mel64) | completed | Phase 1 / Phase 2 | 22 | Craig L Slingluff, JrOTHER | 1 | Aug 25, 2023 |
| clinicaltrials |
| NCT05677373 | Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Alliance for Clinical Trials in OncologyOTHER | 0 | Aug 18, 2023 | clinicaltrials |
| NCT02273219 | Trial of AEB071 in Combination With BYL719 in Patients With Melanoma | completed | Phase 1 | 30 | Columbia UniversityOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05739006 | Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies | unknown | Phase 1 | 131 | BiocadINDUSTRY | 1 | Aug 2, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT01176474 | Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma | completed | Phase 1 | 73 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT04452214 | A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors | completed | Phase 1 | 19 | Cantargia ABINDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05928962 | An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas | unknown | Phase 1 | 10 | Fujian Cancer HospitalOTHER_GOV | 1 | Jul 10, 2023 | clinicaltrials |
| NCT04763083 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | unknown | Phase 1 | 90 | NovalGen Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05451407 | Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma | unknown | Phase 1 | 50 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT03803397 | Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma | unknown | Phase 1 | 10 | PrimeVax Immuno-Oncology Inc.INDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT03989895 | Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma | unknown | Phase 1 | 10 | PrimeVax Immuno-Oncology Inc.INDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT03990493 | Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma | unknown | Phase 1 | 10 | PrimeVax Immuno-Oncology Inc.INDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT01559818 | A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001 | terminated | Phase 1 / Phase 2 | 10 | Immodulon Therapeutics LtdINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03399448 | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | terminated | Phase 1 | 3 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02575404 | GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients | completed | Phase 1 | 36 | Providence Health & ServicesOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT03637803 | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | terminated | Phase 1 / Phase 2 | 63 | 4D pharma plcINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT03973151 | Study of HL-085 in NRAS Mutant Advanced Melanoma | completed | Phase 1 / Phase 2 | 42 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | May 31, 2023 | clinicaltrials |
| NCT00790010 | Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma | completed | Phase 1 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT02961283 | Study of ASN003 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 24 | Asana BioSciencesINDUSTRY | 1 | May 9, 2023 | clinicaltrials |
| NCT03408587 | CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)(CLEVER) | completed | Phase 1 | 11 | ViralyticsINDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT02141542 | Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma | completed | Phase 1 | 15 | F. Stephen Hodi, MDOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | terminated | Phase 1 | 159 | Seagen Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT05723432 | KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma | unknown | Phase 1 / Phase 2 | 84 | Shanghai Kanda Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 27, 2023 | clinicaltrials |
| NCT01191775 | A Study of PNT2258 in Patients With Advanced Solid Tumors | completed | Phase 1 | 22 | Sierra Oncology LLC - a GSK companyINDUSTRY | 1 | Apr 19, 2023 | clinicaltrials |
| NCT04834973 | A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma | terminated | Phase 1 / Phase 2 | 3 | QBiotics Group LimitedINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT03743298 | Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma | unknown | Phase 1 | 20 | Aivita Biomedical, Inc.INDUSTRY | 1 | Apr 10, 2023 | clinicaltrials |
| NCT01164891 | A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma | completed | Phase 1 | 7 | Hoffmann-La RocheINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides | terminated | Phase 1 | 56 | PfizerINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT02120222 | Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery(KPT-330) | completed | Phase 1 | 8 | Kari KendraOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03878719 | Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma | terminated | Phase 1 | 1 | PfizerINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT00667953 | Study of Temzolomide and Gleevec in Advanced Melanoma | terminated | Phase 1 / Phase 2 | 32 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | terminated | Phase 1 | 88 | Seagen Inc.INDUSTRY | 5 | Mar 23, 2023 | clinicaltrials |
| NCT02570308 | A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma | completed | Phase 1 / Phase 2 | 146 | Immunocore LtdINDUSTRY | 5 | Mar 21, 2023 | clinicaltrials |
| NCT02771626 | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 118 | Calithera Biosciences, IncINDUSTRY | 1 | Mar 17, 2023 | clinicaltrials |
| NCT04837677 | A Study of PRT1419 in Patients With Advanced Solid Tumors | completed | Phase 1 | 26 | Prelude TherapeuticsINDUSTRY | 1 | Mar 15, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT02738489 | A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma | completed | Phase 1 | 36 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 28, 2023 | clinicaltrials |
| NCT03689192 | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors | completed | Phase 1 | 13 | Herlev HospitalOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT03265080 | A Study of ADXS-NEO Expressing Personalized Tumor Antigens(NEO) | terminated | Phase 1 | 13 | Advaxis, Inc.INDUSTRY | 1 | Feb 24, 2023 | clinicaltrials |
| NCT04759846 | Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma | withdrawn | Phase 1 | 0 | Pierre Fabre MedicamentINDUSTRY | 3 | Feb 21, 2023 | clinicaltrials |
| NCT02032810 | Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | completed | Phase 1 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT01657591 | Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma | completed | Phase 1 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Aug 28, 2023source: clinicaltrials